Medicare will cover GLP-1 drugs starting July 2026

Why GLP-1 coverage under Medicare was blocked for 20 years

The ban was not accidental. The Medicare Prescription Drug, Improvement, and Modernization Act, passed in 2003, explicitly excluded drugs used for obesity. Congress wrote it that way. For two decades, a Medicare beneficiary with a BMI of 40 and no diabetes diagnosis had no path to covered GLP-1 treatment. People with type 2 diabetes could get Ozempic or Mounjaro through Medicare Part D. Everyone else could not.

The practical result was stark. Many of the people who stood to benefit most from GLP-1s, namely older adults with obesity, hypertension, and cardiovascular risk, paid the full list price or went without.

The Medicare GLP-1 Bridge, announced by CMS in spring 2026, dismantles that for at least 18 months. It is a demonstration project rather than a permanent benefit. But it is real coverage at a price point that makes access possible.

The three BMI tiers that determine if you qualify

CMS structured eligibility around three tiers based on BMI and comorbidities. The logic tracks the clinical evidence: higher BMI opens the door alone, while lower BMI requires a documented cardiovascular or metabolic risk factor to justify coverage.

The SELECT trial, which showed semaglutide cutting major cardiovascular events by 20% in people with obesity and existing heart disease (most without diabetes), is the evidence base Tier 2 and Tier 3 reflect. CMS is not handing this out broadly. They are targeting the population where the benefit-to-risk math is well-established.

For reference on qualifying: the standard BMI threshold for online GLP-1 prescriptions has generally been BMI 27 with a comorbidity or BMI 30 alone. Medicare is using similar goalposts, just formalized differently by tier.

Which GLP-1 drugs are covered, and which are not

Four drugs qualify for the Bridge: Wegovy (semaglutide 2.4 mg weekly injection), Wegovy tablets (oral semaglutide), Zepbound KwikPen (tirzepatide for weight management), and Foundayo (orforglipron, Lilly's oral small-molecule GLP-1 approved earlier this year).

Ozempic and Mounjaro are not covered. Neither is Rybelsus. This confuses people, because Ozempic and Wegovy contain the same active ingredient. The difference is the label. Ozempic carries a diabetes indication. Wegovy carries a weight management indication. The Bridge covers weight management prescriptions only. The indication on the prescription matters, not the molecule.

If your doctor writes an Ozempic script and your pharmacist processes it as a diabetes claim, the Bridge does not apply. The prescription has to be for the weight management formulation. Providers familiar with Medicare billing will know the distinction. Make sure yours does.

Compounded versions are also excluded. The FDA's current rulemaking, with a public comment period open through late June 2026, would permanently close the compounding pathway for semaglutide and tirzepatide. If you currently use compounded GLP-1s, the Bridge does not help you directly, and the longer-term outlook for compounded access is uncertain.

How the prior authorization works

You do not register for the program. No opt-in, no enrollment form on your end. The mechanism is entirely through your doctor's office. Your prescriber submits a prior authorization request attesting to your BMI and, where applicable, the qualifying comorbidity. CMS processes it through a single central processor in 2026.

That central processor is new and worth noting. Before this, PA decisions for GLP-1s were handled plan-by-plan. Patients on different Medicare Advantage plans with identical clinical profiles could get different decisions. The single processor is designed to standardize approvals across Part D plans and Medicare Advantage drug plans alike.

Any eligible plan type participates: standalone prescription drug plans (PDPs) and Medicare Advantage coordinated care plans with drug coverage (MA-PDs). You do not need to change your plan or switch carriers.

The practical advice: do not wait until July 1. Talk to your doctor now. Confirm your most recent BMI measurement. Identify which tier you fall into. Ask your doctor's office to prepare the PA form as soon as CMS releases the official template. The queue will build as July approaches, and delays in PA processing mean delays in access.

What $50 a month actually means

Wegovy's list price is approximately $1,350 per month. Manufacturer savings programs can bring that to $0 to $25 for commercially insured patients. Those programs explicitly exclude Medicare beneficiaries. Federal anti-kickback rules prevent drug companies from offering price reductions to patients on government insurance. So before the Bridge, most Medicare beneficiaries with obesity but no diabetes faced the full list price or nothing.

$50 per month is not free. But it is a 96% reduction from list price for people who had no other option. For someone on a fixed income who meets the clinical criteria, that difference determines whether treatment happens at all.

For context on how GLP-1 costs compare across different coverage scenarios, including commercial insurance, compounding, and manufacturer programs, the gaps can be significant. The Bridge closes the largest of those gaps for Medicare beneficiaries.

What happens when the Bridge ends in December 2027

The program has a hard end date: December 31, 2027. CMS is simultaneously running the BALANCE model, a separate demonstration through 2030 that covers Medicare and Medicaid enrollees and focuses on collecting long-term outcomes data. The question BALANCE is designed to answer is whether GLP-1 coverage reduces hospitalizations, cardiovascular events, and total healthcare spending enough to justify the drug costs.

Permanent Medicare coverage requires Congress. The Congressional Budget Office has estimated the cost in the hundreds of billions over a decade. The clinical evidence supporting coverage is strong. Those two facts will collide in the 2027 budget debate, and the outcome is genuinely uncertain.

If you start treatment under the Bridge and coverage ends without a legislative solution, you will need a plan. Options include manufacturer patient assistance programs, Medicare Extra Help for low-income beneficiaries, or switching to a covered diabetes indication if you qualify. None of these are seamless. The guidance is to plan for this now rather than assume continuity.

For a broader picture of what the next generation of GLP-1 options looks like, including oral formulations like the Wegovy tablet now covered under the Bridge, and where the pipeline goes from here, the drug options available under Medicare coverage will expand as approvals proceed.